The FDA has created the Drug Trial Snapshot, which provides details on the demographic profiles of participants in clinical trials of approved drugs.
Historically, the design of clinical trials to evaluate specific drugs has been in a controlled environment. The study population enrolled in a trial is very carefully chosen, with specific inclusion and exclusion criteria for trial subjects. However, in the real world, the drug will be prescribed to a diverse population of patients, each with a distinct genetic profile that can result in significant differences in drug exposure, absorption, metabolism, outcomes, and adverse effects.
Several studies have noted the lack of diversity in clinical trials. Physicians usually base their treatment decisions by extrapolating the results of trial data from a relatively homogenous population of white males. With a near-equal split in the percentage of males and females in the US, and with racial and ethnic minorities making up nearly 40% of the population, heterogeneity in clinical trials would be extremely valuable. Another population that is usually underrepresented in clinical trials are the elderly. Medications developed for a lot of chronic conditions are most often than not used by the elderly, and the 65-plus is the fastest growing segment of the global population.
A study conducted by researchers at the University of California, Davis, found that while cancer clinical trial participation is low for all adult groups (3-5%), the percentage of minorities who participate in clinical trials is not representative of the US population affected by cancer. For example, blacks experience the highest incidence of cancer (593.7 cases per 100,000 people) but, along with Hispanics, have the lowest rates of cancer clinical trials participation at 1.3%.
Responding to these concerns, the FDA, under direction by the Congress, has been paying greater attention to study subject diversity in clinical trials. The directive from the Congress was included in Section 907 of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, and in response, the FDA created the Drug Trial Snapshot, which provides details on the demographic profiles of participants in clinical trials of approved drugs. The Snapshot would thereby be the go-to page for patients and providers alike to understand the responses of specific groups of patients to these drugs.
This effort can have a tremendous impact on the quality of care as well as downstream costs of care for the health system as a whole. Inclusion of more women, minorities, and the older population in a drug trial can help drug developers as well as providers better understand clinical presentation and response to the drug being developed in a wider demographic. A skewed pool of participants could miss important drug-gene interactions. A clear understanding of a drug’s effects across the population can potentially reduce experimentation by physicians once the drug is approved for use in the clinic.
To that end, the FDA is planning numerous efforts in 2016 to push for greater inclusion in trial populations:
What is needed is a concerted effort from various agencies and policy changes to push greater inclusion and avoid disparities in clinical trials.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More